青光眼手術設備的全球市場(2023年):2022年～2028年的分析

在過去幾年中，手術器械的選擇增加了一倍多，隨著新器械數量的開發，預計未來五年將繼續快速擴張。該報告分析了這些競爭對手產品數量的成長情況，並按類型繪製了預期成長情況。還在單獨部分中追蹤持續給藥裝置的發展。

範例視圖

本報告提供全球青光眼手術設備市場相關調查，提供市場概要，以及今後5年的市場預測，重要的未來趨勢，及加入此市場的主要企業的競爭分析等資訊。

目錄

• 青光眼，青光眼人口，青光眼診斷相關背景資訊。
• 青光眼手術設備的含目前銷售額估計·預測銷售額(平均價格和總收入)
• 眼科醫生，眼科專門醫生，驗光師，含一般醫生的設備購買預定者的簡介
• 廠商相關資訊
• 目前償付率

What's New:

The "2023 Glaucoma Surgical Device Market Report" analyzes a new trend in the treatment of glaucoma patients: earlier surgical intervention. The report projects market growth through 2028 and discusses the mix of combination cataract/glaucoma surgeries and standalone glaucoma procedures for eight regions of the world.

SAMPLE VIEW

Glaucoma laser technologies in development or early commercialization are expected to significantly increase overall laser penetration. The new report highlights some of these technologies, including the Belkin laser, ViaLase femtosecond laser, Elios excimer laser, and IOPtimate CO2 laser.

Surgical device options in the past few years have more than doubled, and rapid expansion is expected to continue over the next five years, based on the number of new devices in development. The report analyzes this growing number of products from each competitor and illustrates the expected increase by type. It also tracks the progress being made in sustained drug delivery devices in a separate section.

The "2023 Glaucoma Surgical Device Market Report" offers a comprehensive analysis of the current global market for glaucoma devices, as well as a discussion of important trends and key factors shaping future success. The report covers prevalence for glaucoma worldwide and discusses the ophthalmologists who treat glaucoma. It also examines the role of surgical intervention, the market dynamics for currently commercialized products, and the pipeline of investigational devices that may offer improved outcomes. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Twenty-four market competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

Contents:

The report mainly focuses on the product categories of microstents, formerly referred to as minimally invasive glaucoma surgery (MIGS) devices; subconjunctival shunts; canal surgery devices; and tube shunts. It also examines lasers used in glaucoma procedures. Each segment provides an analysis of market competitors and five-year market forecasts for units and dollars.

Also included in the report:

• Background information about glaucoma, glaucoma populations, and glaucoma diagnosis.

• Estimates of current sales and sales forecasts for glaucoma devices, including average prices and total revenue.

• Profiles of prospective device buyers, including ophthalmologists, ophthalmic specialists, optometrists, and general medical doctors.

• Information about manufacturers.

• Current reimbursement rates.

Author Profile:

William Freeman

Bill Freemanhas more than 35 years of experience developing, manufacturing, and marketing cataract surgery products. He has held key executive positions at four firms that produce ophthalmic surgical devices.

Bill's career in ophthalmology began in the 1970s. As president of Cavitron Surgical Systems, he worked with Dr. Charles Kelman in developing and marketing the world's first phacoemulsifier system. While highly controversial in the 1970s, phacoemulsification gradually became the preferred cataract removal technique in the early 1980s. For many years, Cavitron led the cataract instrumentation market.

CooperVision purchased Cavitron in the early 1980s, and Bill joined the company as president of the surgical division. CooperVision expanded its product line to include a wide variety of cataract surgical products-IOLs, viscoelastic solutions, disposable devices, lasers, and custom packs-and became the market leader in many product categories.

In 1989, Alcon acquired CooperVision in an effort to build a strong presence in cataract surgical devices. Bill joined Alcon as general manager of the Irvine Technology Center, where a number of the company's cataract devices, including the Legacy 20000 phacoemulsifier and a broad line of disposable items, were designed and manufactured.

Bill remained with Alcon until 1995. He then joined Mentor Ophthalmics as president of the ophthalmology division. At Mentor, he was responsible for the company's ophthalmic products including IOLs, cautery devices, and surgical instruments.

After leaving Mentor in 1999, Bill joined Market Scope in 2000 and now serves as executive vice president focusing on ophthalmic surgical cataract, retinal and glaucoma devices.